Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Gil

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Pharmaceuticals (Basel, Switzerland)|April 27, 2024
Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?Anna Gil-Sánchez, Hugo Gonzalo, Marc Canudes, et al.
Molecular Neurobiology|June 17, 2026
18:2 Cholesterol Ester is a Novel Prognostic Biomarker of Disease Progression in Multiple SclerosisPascual Torres, Anna Gil Sánchez, Agustín Sancho-Saldaña, et al.
International Journal of Medical Sciences|August 29, 2013
Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary culturesJosé M Palanca, Diana Aguirre-Rueda, Manuel V Granell, et al.
Journal of Neurology|March 18, 2023
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapiesPascual Torres, Agustín Sancho-Saldaña, Anna Gil Sánchez, et al.
Scientific Reports|November 8, 2023
Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot studyCristina González Mingot, Sonia Santos Lasaosa, Laura Colàs Campàs, et al.
Journal of Clinical Medicine|June 13, 2025
Profile of Cytokines Associated with SARS-CoV2 Seropositivity in Multiple Sclerosis Patients and Its Persistence over Six MonthsAgustín Sancho-Saldaña, Anna Gil-Sánchez, Bibiana Quirant-Sánchez, et al.
Frontiers in Neuroscience|September 26, 2019
Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis PatientsHugo Gonzalo, Lara Nogueras, Anna Gil-Sánchez, et al.
Journal of Clinical Medicine|May 14, 2022
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying TherapiesAgustín Sancho-Saldaña, Anna Gil Sánchez, Bibiana Quirant-Sánchez, et al.
The International Journal of Neuroscience|May 5, 2016
A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patientsAnna Gil Sánchez, Eugenia Lacasa Andrade, Joan Valls Marsal, et al.
Frontiers in Rehabilitation Sciences|January 6, 2023
Cognitive assessment in patients with multiple sclerosis: A Spanish consensusYolanda Higueras, Mónica Borges, Isabel Jiménez-Martín, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Pharmaceuticals (Basel, Switzerland)|April 27, 2024
Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?Anna Gil-Sánchez, Hugo Gonzalo, Marc Canudes, et al.
Molecular Neurobiology|June 17, 2026
18:2 Cholesterol Ester is a Novel Prognostic Biomarker of Disease Progression in Multiple SclerosisPascual Torres, Anna Gil Sánchez, Agustín Sancho-Saldaña, et al.
International Journal of Medical Sciences|August 29, 2013
Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary culturesJosé M Palanca, Diana Aguirre-Rueda, Manuel V Granell, et al.
Journal of Neurology|March 18, 2023
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapiesPascual Torres, Agustín Sancho-Saldaña, Anna Gil Sánchez, et al.
Scientific Reports|November 8, 2023
Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot studyCristina González Mingot, Sonia Santos Lasaosa, Laura Colàs Campàs, et al.
Journal of Clinical Medicine|June 13, 2025
Profile of Cytokines Associated with SARS-CoV2 Seropositivity in Multiple Sclerosis Patients and Its Persistence over Six MonthsAgustín Sancho-Saldaña, Anna Gil-Sánchez, Bibiana Quirant-Sánchez, et al.
Frontiers in Neuroscience|September 26, 2019
Impairment of Mitochondrial Redox Status in Peripheral Lymphocytes of Multiple Sclerosis PatientsHugo Gonzalo, Lara Nogueras, Anna Gil-Sánchez, et al.
Journal of Clinical Medicine|May 14, 2022
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying TherapiesAgustín Sancho-Saldaña, Anna Gil Sánchez, Bibiana Quirant-Sánchez, et al.
The International Journal of Neuroscience|May 5, 2016
A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patientsAnna Gil Sánchez, Eugenia Lacasa Andrade, Joan Valls Marsal, et al.
Frontiers in Rehabilitation Sciences|January 6, 2023
Cognitive assessment in patients with multiple sclerosis: A Spanish consensusYolanda Higueras, Mónica Borges, Isabel Jiménez-Martín, et al.
Pageof 5